← Back to Search

Newly diagnosed NSCLC stage IV for Non-Small Cell Lung Cancer (PROPHETIC Trial)

N/A
Recruiting
Led By Ido Wolf, MD
Research Sponsored by OncoHost Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at end of study (2 years)
Awards & highlights

Summary

This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma who could benefit from cancer treatment they receive.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Malignant Melanoma
  • Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at end of study (2 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and at end of study (2 years) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in the blood levels of different proteins that represent the host response
Overall response rate (ORR) at 3 months
Overall response rate (ORR) at 6 months
Other study objectives
Adverse Events (AE)
Duration of Response (DOR)
Overall Survival (OS)
+1 more

Trial Design

5Treatment groups
Experimental Treatment
Group I: SCLC stage IVExperimental Treatment1 Intervention
Patients with stage IV SCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
Group II: Newly diagnosed NSCLC stage IVExperimental Treatment1 Intervention
Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
Group III: NSCLC stage IV 2nd line and further of immunotherapyExperimental Treatment1 Intervention
Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive lines.
Group IV: Malignant melanoma stage IVExperimental Treatment1 Intervention
Patients with stage IV malignant melanoma treated with Immunotherapy with or without targeted therapy.
Group V: Malignant melanoma stage IIIb-dExperimental Treatment1 Intervention
Patients with stage IIIb-d malignant melanoma treated with Immunotherapy as adjuvant therapy.

Find a Location

Who is running the clinical trial?

OncoHost Ltd.Lead Sponsor
2 Previous Clinical Trials
1,350 Total Patients Enrolled
Ido Wolf, MDPrincipal Investigator002 Tel Aviv Sourasky Medical Center
1 Previous Clinical Trials
30 Total Patients Enrolled
Petros Christopoulos, MDPrincipal Investigator041 Thoraxklinik-Heidelberg gGmbH
1 Previous Clinical Trials
400 Total Patients Enrolled
~1000 spots leftby Oct 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top